Allan Jonathan sold $92K of STOK

Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 2,861 shares of Stoke Therapeutics, Inc. (STOK) at an average of $32.03 ($32.01–$32.47) across 2 trades on 2026-08-18.

Original reporting
SEC EDGAR · Allan Jonathan
Published Aug 19, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STOK
Neutral
high confidence
Mentioned
$STOK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership after an open-market sale by the company’s general counsel and corporate secretary role.

02

Market read

Traders may note insider selling, but the filing lacks any new company catalyst, so it is unlikely to materially reprice the stock by itself.

03

What to watch

The article provides only sale details, not context such as option exercises, tax planning, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18 after-hours; reflects sale executed on 2026-08-18

Background

The article is a SEC Form 4 insider transaction disclosure for Stoke Therapeutics, Inc.

Company-level read

Ticker impact

$STOKNeutralHigh confidence
Context

Stoke Therapeutics insider Allan Jonathan sold about $91.6K of STOK shares on 2026-08-18 via an open-market sale.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a new operating catalyst.

Evidence & confidence

The filing is a small, non-10b5-1 sale with no accompanying company news, guidance, or operational update in the text.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide regulatory or clinical update.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or tax needs; the absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • Stoke Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure (STOK).

  • Allan Jonathan

    General Counsel and corporate SEC role; sold 2,861 shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.